Ulcerative colitis (UC) has been proven to have an economic and physical burden upon patients,
with an associated mortality of up to 2.9%. However, morbidity and mortality have peaked
since the breakout Coronavirus disease 2019 )COVID-19( pandemic as result of direct relationship
between Inflammatory bowel disease (IBD) severity and adverse outcome from severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
This study evaluated the efficacy and safety of inactivated COVID 19 vaccine (e.g. Sinopharm)
in UC patients receiving anti-tumor necrosis factor (TNF) as compared to normal hea lthy
population receiving the same type of vaccine 3 months after the last dose of vaccination.
The results showed those twenty patients with ulcerative colitis and on Anti TNF treatment
(GA), and 20 healthy controls (GB). In GA; the mean age was (31.65) years, included 12
females (60%) and 8 males (40%). While in GB; the mean age was (30.55) years, with 11 males
(55%) and 9 females (45%) without significant difference between both as to age (P=0.459) or
sex (P=0.619). In GA only 16 (80%) had positive anti-spike IgG versus 18 posit- ives in GB
(90%) without significant difference. Anti-spike IgG titre after 3 months with median ranges of
33.5 (RU/ml) in IBD patients and 44.5 (RU/ml) in controls with significant difference between
both (P=0.025). There was no significant difference between both groups as to pain at injection
site, skin allergy and generalized symptoms (fatigue, fever, chills, headache, muscles and joints
pain).